TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003667
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003667
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02559232
Drug: Direct Oral Anticoagulant (DOAC)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment pattern following the summary of product characteristics
Study: NCT03485365
Drug: GSK3858279 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3858279 will be available as solution for injection to be administered via IV route.
Study: NCT03485365
Drug: GSK3858279 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3858279 will be available as solution for injection to be administered via SC route.
Study: NCT03485365
Drug: Placebo matching to GSK3858279 (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as sodium chloride solution to be administered via SC route.
Study: NCT01798316
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
Study: NCT01798316
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care pain management regimen, no IV Acetaminophen,
Study: NCT02699515
Drug: MSB0011359C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Study: NCT00204893
Drug: calcium formate
Normalized name: Calcium formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
Study: NCT00814073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03787368
Drug: BAY1213790
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of BAY1213790 (Two different doses)
Study: NCT02618850
Drug: first-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: as prescribed by oncologist
Study: NCT04359823
Drug: Lovastatin 2%, 2% Cholesterol Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
Study: NCT04359823
Drug: Lovastatin 2% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
Study: NCT00452101
Drug: Aquamin F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03866993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02219555
Drug: Steroid Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: volume and specific steroid drug will be based on the recommendation of the treating clinician
Study: NCT04814355
Drug: Celecoxib 400 mg
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 400 mg/day of celecoxib for 8 weeks.
Study: NCT04450355
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous normal saline infusion
Study: NCT00384930
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth one a day for twelve weeks
Study: NCT03978494
Drug: Advagraf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
Study: NCT01879605
Drug: Docusate natrium and sorbitol
Normalized name: docusate / sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00089843
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch 150mcg daily
Study: NCT00089843
Drug: Placebo Actonel (risedronate)
Normalized name: risedronate Oral Tablet [Actonel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet identical in appearance to active Actonel (risedronate) tablet
Study: NCT00089843
Drug: Placebo testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch identical in appearance to testosterone patch
Study: NCT01386580
Drug: 2B3-101 60 mg/m2 every 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV every 28 days
Study: NCT01386580
Drug: 2B3-101 50 mg/m2 every 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV every 21 days
Study: NCT00921505
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet ibuprofen 400 mg oral single dose (1 tablet)
Study: NCT00921505
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets (2 x 600 mg) oral single dose (2 tablets)
Study: NCT00921505
Drug: Paracetamol + ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
Study: NCT01392989
Drug: CIK cells
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT04420871
Drug: 150 mg of capecitabine
Normalized name: capecitabine 150 MG
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
Study: NCT03940651
Drug: General Anesthetics
Normalized name: GENERAL ANESTHETICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to type of anesthesia
Study: NCT02361242
Drug: PXT00864
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate
Study: NCT03218852
Drug: prednisone and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone and cyclophosphamide are both administered to participants in this group.
Study: NCT00589888
Drug: Intralipid 20% @ 20cc/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
Study: NCT00589888
Drug: Intralipid 20%@ 40cc/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
Study: NCT00589888
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
Study: NCT03800706
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
Study: NCT04492956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02388529
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study: NCT02388529
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study: NCT02388529
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study: NCT02388529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
Study: NCT03613090
Drug: Collagen-hydroxyapatite scaffold (Syn-Oss)
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
Study: NCT03613090
Drug: Collagen Scaffold (Colla-Plug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
Study: NCT00559052
Drug: VIOKASE 16
Normalized name: Viokase 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
Study: NCT00428506
Drug: albumin 4 gr/L ascites removed
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin 4 gr/L ascites removed
Study: NCT00428506
Drug: albumin 8 gr/L ascites removed
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin 8 gr/L ascites removed
Study: NCT01857843
Drug: Ezetimibe 10mg & Simvastatin 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)
Study: NCT01857843
Drug: Pravastatin 20mg
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)
Study: NCT04221906
Drug: BOS-475
Normalized name: BOS TAURUS EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream
Study: NCT01492647
Drug: JNJ 10229570-AAA 1.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Study: NCT01492647
Drug: JNJ 10229570-AAA 3.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Study: NCT04312113
Drug: Adipose derived, autologous mesenchymal stem cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
Study: NCT02752087
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03066817
Drug: Propylene Glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50cc of propylene glycole will be given to participants as one-time dose, used as placebo
Study: NCT01286844
Drug: GSK2190915A 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral powder for dispersion in water
Study: NCT01286844
Drug: GSK2190915A 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral powder for dispersion in water
Study: NCT01286844
Drug: GSK2190915A 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral powder for dispersion in water
Study: NCT01286844
Drug: GSK2190915A 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral powder for dispersion in water
Study: NCT01286844
Drug: GSK2190915A 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral powder for dispersion in water
Study: NCT00069095
Drug: Leucovorin 200 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
Study: NCT00069095
Drug: Fluorouracil 400 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02005653
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental
Study: NCT02660424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00543751
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01370798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
Study: NCT03384290
Drug: PRS-060
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT03384290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRS-060 Matching Placebo
Study: NCT02794493
Drug: Traditional Chinese Medicine Formula LC09
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01750268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00025259
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00025259
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03321292
Drug: L-arginine 1000 mg and Acetylesalicylic acid75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
Study: NCT03321292
Drug: acetylsalicylic acid 75 mg
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
Study: NCT02399475
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
Study: NCT02399475
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
Study: NCT01476332
Drug: cis-urocanic acid 0,5% eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study: NCT01476332
Drug: cis-urocanic acid 2.5% eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study: NCT01476332
Drug: Placebo for cis-UCA, eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study: NCT00003859
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02682888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo
Study: NCT00048737
Drug: Zevalin Radioimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
Study: NCT00048737
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
Study: NCT01000064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken every morning for 6 weeks.
Study: NCT02354170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03777956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo are given as capsules and taken orally twice a day.
Study: NCT00606697
Drug: GR205171
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 milligrams (mg)
Study: NCT00606697
Drug: GW597599
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg
Study: NCT00176566
Drug: Lozenge Intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
Study: NCT01518192
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg bid; 15 days
Study: NCT00085540
Drug: depsipeptide
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00798967
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
Study: NCT02474017
Drug: MGR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
Study: NCT02444897
Drug: IV PCA Fentanyl+nefopam+Ramosetron
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
Study: NCT00001262
Drug: Copper Histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04013581
Drug: TZD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
Study: NCT04013581
Drug: SGLT-2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
Study: NCT02180737
Drug: Dexmeditomedine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00096746
Drug: LPV/RTV + 2NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Variable, Twice daily, 48 weeks.
Study: NCT00817986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT03047993
Drug: Glutaminase Inhibitor CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00517556
Drug: CCOCP
Normalized name: Calcium Carbonate and Cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: (CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
Study: NCT00774735
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg given in combination with lopinavir/ritonavir
Study: NCT00774735
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg in combination with darunavir/ritonavir
Study: NCT02505087
Drug: N-Acetylcysteine followed by Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout.
Study: NCT04207112
Drug: Standard Drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Study: NCT02505087
Drug: Placebo followed by N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
Study: NCT00700297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet placebo per day for 4 months
Study: NCT01253512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT00108849
Drug: estradiol, 10 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04592380
Drug: Stage 1: Placebo (double-blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
Study: NCT04592380
Drug: Stage 2: Standard of Care (open-label)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
Study: NCT02041715
Drug: TKM-100802 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02041715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion